Latest pharmaceutical industry Stories
DUBLIN, April 25, 2013 /PRNewswire/ -- Research and Markets has announced the addition of the "Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech, 3rd Edition [http://www.researchandmarkets.com/research/bsnx9p/preclinical_stage ]" report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) The Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech report provides comprehensive understanding and...
DUBLIN, Ireland, April 25, 2013 /PRNewswire/ -- Research and Markets has announced the addition of the "PharmaLeaders: Generic Manufacturers Benchmark Report - Financial Benchmarking & Competitive Analysis of the Leading Generic Players in 2013 [http://www.researchandmarkets.com/research/sq6vs2/pharmaleaders ]" report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Sun Shines on Indian Generics Manufacturers India is...
- 180 Days of Exclusivity - PARSIPPANY, N.J., April 25, 2013 /PRNewswire/ -- Actavis, Inc. (NYSE: ACT), a leading specialty pharmaceutical company, today announced that is has reached a settlement agreement with Shire plc resolving outstanding patent litigation related to Actavis' generic version of INTUNIV(®) (guanfacine hydrochloride) for the treatment of Attention Deficit Hyperactivity Disorder. The settlement also resolves outstanding litigation against legacy Watson's...
Genentech Ranks Highest in Physician Satisfaction with Biopharmaceutical Manufacturers WESTLAKE VILLAGE, Calif., April 25, 2013 /PRNewswire/ -- Although the role of pharmaceutical sales representatives has changed in recent years, physicians continue to perceive the sales representative as the leading influence on their relationship with biopharmaceutical companies, according to the J.D. Power and Associates 2013 Physician Manufacturer Experience Study--Oncology(SM )released today....
THE WOODLANDS, Texas, April 25, 2013 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that Arthur Sands, M.D., Ph.D., president and chief executive officer, will present at the Needham Healthcare Conference on Tuesday, April 30, at 2:20 PM EST in New York City. Dr. Sands will provide an overview of Lexicon's clinical development programs and milestones. A webcast of the presentation will be available through Lexicon's website at www.lexpharma.com....
COPENHAGEN, Denmark, April 25, 2013 /PRNewswire/ -- - Roll-out of Agnitio's software and services with Allergan Agnitio, the pharmaceutical industry's pull marketing leader, is seeing a significant increase in the roll-out of its closed loop marketing software suite and services to major global healthcare companies. (Logo: http://photos.prnewswire.com/prnh/20120924/562917-a ) (Photo: http://photos.prnewswire.com/prnh/20130320/601933 )...
ZURICH, April 25, 2013 /PRNewswire/ -- - Phase 2b clinical trial of CYT003 in allergic asthma on-going as planned - Cytos' VLP platform is basis for a phase 1 clinical trial with an Anti-lgE Vaccine partnered with and conducted by Pfizer - Management team further strengthened - The Journal of Allergy and Clinical Immunology publishes phase 2a...
Emerson Ecologics Selected as the Primary Partner as Heel Moves All Product Fulfillment to Distribution MANCHESTER, N.H., April 24, 2013 /PRNewswire/ -- Emerson Ecologics, LLC, the leading provider of the highest quality professional nutritional supplements to healthcare practitioners and their patients for over 30 years, today announced their expanded strategic partnership with Heel Inc., a homeopathic pharmaceutical manufacturer committed to quality. Effective today April 24,...
INDIANAPOLIS, April 24, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) has been named to the DiversityInc "Top 50 Companies for Diversity" list for the third consecutive year. DiversityInc's "Top 50 Companies for Diversity" is known as a leading assessment of diversity management globally. To make the list, participating companies must have more than 1,000 employees and demonstrate strength in key diversity areas: CEO commitment, human capital, corporate and organizational...
- HarborPath Partners Now Include Gilead Sciences, Merck and ViiV Healthcare - COLUMBIA, S.C., April 24, 2013 /PRNewswire/ -- HarborPath, an organization which provides a single point of access to HIV/AIDS medications through patient assistance programs, welcomes Gilead Sciences as a participating company. Gilead joins Merck and ViiV Healthcare as the third pharmaceutical company to support HarborPath since its launch in July 2012. "With Gilead's support of this pilot program, we...
